<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:media="http://search.yahoo.com/mrss/"><channel><title>Zibb.com: Cephalon Incorporated (Web)</title><link>http://www.zibb.com/all/theme/cq/Cephalon+Incorporated</link><atom:link rel="self" type="application/rss+xml" href="http://www.zibb.com/all/theme/cq/Cephalon+Incorporated" /><description>
					Zibb. The Global business search engine.
				</description><language>
					en-US
				</language><webMaster>search@zibb.com (RB Search)</webMaster><copyright>Copyright (c) 2007 Reed Business Information. All rights reserved.</copyright><pubDate>Tue, 27 Oct 2009 10:59:22 GMT</pubDate><lastBuildDate>Tue, 27 Oct 2009 10:59:22 GMT</lastBuildDate><ttl>60</ttl><image><title>Zibb.com: Cephalon Incorporated (Web)
          </title><width>88</width><height>31</height><link>http://www.zibb.com/all/theme/cq/Cephalon+Incorporated</link><url>
						http://www.zibb.com/images/en/g_zibb_logo_beta.gif
					</url></image><item><title>Cephalon Net Sales Increase 9% and Net Cash from Operations Surpa...
      </title><link>http://www.bio-medicine.org/medicine-technology-1/Cephalon-Net-Sales-Increase-9-25-and-Net-Cash-from-Operations-Surpasses--24200-Million-in-the-Third-Quarter-2009-5760-1/</link><description>...FRAZER Pa. Oct. 27 /- Cephalon Inc. (Nasdaq:...Central nervous system (CNS) franchise net sales were $291.9 million d...During the quarter Cephalon recorded net cash provided by operating ac... The exceptional launch of NUVIGIL was the highlight of the quarter</description><guid>http://www.bio-medicine.org/medicine-technology-1/Cephalon-Net-Sales-Increase-9-25-and-Net-Cash-from-Operations-Surpasses--24200-Million-in-the-Third-Quarter-2009-5760-1/</guid><category domain="http://www.zibb.com">Cephalon Incorporated</category><pubDate>Tue, 27 Oct 2009 10:59:22 GMT</pubDate><source url="http://www.bio-medicine.org" /></item><item><title>Cephalon, The specialist in Neuro and fMRI applications - Neuroim...
      </title><link>http://www.cephalon.dk/</link><description>Our solutions are used in a wide range of applications in the field of neuropsychological, psychologically, ophthalmology and sleep diseases. Customers are Hospitals, private doctors and research lab around the Scandinavian countries.</description><guid>http://www.cephalon.dk/</guid><category domain="http://www.zibb.com">Cephalon Incorporated</category><pubDate /><source url="http://www.cephalon.dk" /></item><item><title>C CEPHALON DELIVER MORE</title><link>http://it.zibb.com/trademark/c+cephalon+deliver+more/30681894</link><description>C Cephalon Deliver More ǂ C Cephalon Deliver More® is a registered trademark used for Pharmaceutical and Biotechnology Research and Development Services, Namely Developing Diagnostic and Therapeutic Agents To Diagnose and Treat Neurological and Psychiatric Diseases, Cancer, Sleep Disorders and</description><guid>http://it.zibb.com/trademark/c+cephalon+deliver+more/30681894</guid><category domain="http://www.zibb.com">Cephalon Incorporated</category><pubDate /><source url="http://it.zibb.com" /></item><item><title>Cephalon UK | neurological disorders | diseases of the nervous sy...
      </title><link>http://www.cephalon.co.uk/</link><description>Cephalon is one of the world s fastest growing biopharmaceutical companies, currently marketing more than twenty products internationally in the field of central nervous system, pain and oncology.</description><guid>http://www.cephalon.co.uk/</guid><category domain="http://www.zibb.com">Cephalon Incorporated</category><pubDate /><source url="http://www.cephalon.co.uk" /></item><item><title>United States Senator Arlen Specter, Pennsylvania :: News Room</title><link>http://specter.senate.gov/public/index.cfm?FuseAction=NewsRoom.Events&amp;ContentRecord_id=3e0fbb42-9997-c893-04c7-41dbf3c7e8f6&amp;Region_id=&amp;Issue_id=&amp;IsPrint=true</link><description>U.S. Senator Arlen Specter will meet with employees at Cephalon to discuss economic and technology issues. Location: Cephalon Corporate Headquarters 41 Moores Road Frazer, PA 19355 U.S.</description><guid>http://specter.senate.gov/public/index.cfm?FuseAction=NewsRoom.Events&amp;ContentRecord_id=3e0fbb42-9997-c893-04c7-41dbf3c7e8f6&amp;Region_id=&amp;Issue_id=&amp;IsPrint=true</guid><category domain="http://www.zibb.com">Cephalon Incorporated</category><pubDate /><source url="http://specter.senate.gov" /></item><item><title>Cephalon Error</title><link>http://www.cephalon.com/ur_business/education.aspx</link><description>Cephalon Inc. Logo Home | Contact Us | Cephalon Sites | Site Index Cephalon Inc. Investor Relations Brand Photograph Our Business Products Cephalon Science Patients and Physicians Investor Information Newsroom Careers Sorry, the file you requested was not found. Cephalon Inc. Footer Copyright 2006.</description><guid>http://www.cephalon.com/ur_business/education.aspx</guid><category domain="http://www.zibb.com">Cephalon Incorporated</category><pubDate /><source url="http://www.cephalon.com" /></item><item><title>Cephalon licenses lupus drug candidate - Forbes.com</title><link>http://www.forbes.com/feeds/ap/2009/02/02/ap5994979.html</link><description>Cephalon Inc. said Monday it is exercising an option to worldwide licensing rights to a lupus drug that is under development, triggering a $30 million fee to ImmuPharma PLC.</description><guid>http://www.forbes.com/feeds/ap/2009/02/02/ap5994979.html</guid><category domain="http://www.zibb.com">Cephalon Incorporated</category><pubDate /><source url="http://www.forbes.com" /></item><item><title>Improving Patient Safety With RFID-Enabled Packaging And Logisti</title><link>http://www.logisticsonline.com/read/sp20070515/641509</link><description>Cephalon, Inc. is an international biopharmaceutical company dedicated to the discovery, development and marketing of innovative products in four core therapeutic areas: central nervous system, pain, oncology and addiction. The company currently markets six proprietary products in the United States.</description><guid>http://www.logisticsonline.com/read/sp20070515/641509</guid><category domain="http://www.zibb.com">Cephalon Incorporated</category><pubDate /><source url="http://www.logisticsonline.com" /></item><item><title>QAD, Manufacturing ERP Solutions, Enterprise Applications for Glo...
      </title><link>http://www.qad.com/vgn-ext-templating/v/index.jsp?vgnextoid=9f6d647d3109d010VgnVCM100000810903a7RCRD&amp;cpsextcurrchannel=1</link><description>In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.</description><guid>http://www.qad.com/vgn-ext-templating/v/index.jsp?vgnextoid=9f6d647d3109d010VgnVCM100000810903a7RCRD&amp;cpsextcurrchannel=1</guid><category domain="http://www.zibb.com">Cephalon Incorporated</category><pubDate /><source url="http://www.qad.com" /></item><item><title>Copyright © 2009 MarketWatch, Inc. All rights reserved. Please se...
      </title><link>http://www.holdrs.com/holdrs/main/index.asp?Action=Headlines&amp;Description=&amp;Image=&amp;symb=CEPH&amp;sid=7604</link><description>Copyright © 2009 MarketWatch, Inc. All rights reserved. Please see our Terms of Use. MarketWatch, the MarketWatch logo, and BigCharts are registered trademarks of MarketWatch, Inc. Intraday data provided by Interactive Data Real-Time Services and subject to the Terms of Use.</description><guid>http://www.holdrs.com/holdrs/main/index.asp?Action=Headlines&amp;Description=&amp;Image=&amp;symb=CEPH&amp;sid=7604</guid><category domain="http://www.zibb.com">Cephalon Incorporated</category><pubDate /><source url="http://www.holdrs.com" /></item><item><title>Revia PBS Listing Media Release</title><link>http://www.orphan.com.au/PressReleases/actiqpr.html</link><description>WEST CHESTER, Pa., June 12 /PRNewswire/ -- Cephalon, Inc. (Nasdaq: CEPH), an international biopharmaceutical company, announced today that it has granted rights to market, sell and distribute ACTIQ® (oral transmucosal fentanyl citrate) to Orphan Australia for Australia and New Zealand.</description><guid>http://www.orphan.com.au/PressReleases/actiqpr.html</guid><category domain="http://www.zibb.com">Cephalon Incorporated</category><pubDate /><source url="http://www.orphan.com.au" /></item><item><title>eyeforpharma - article search</title><link>http://www.eyeforpharma.com/search.asp?news=43021</link><description>PITTSBURGH (August 23, 2004)- Cephalon is using DiaryPRO, invivodata's eDiary system, to collect pivotal Patient Reported Outcomes (PRO) data in four Phase III clinical trials of armodafinil.</description><guid>http://www.eyeforpharma.com/search.asp?news=43021</guid><category domain="http://www.zibb.com">Cephalon Incorporated</category><pubDate /><source url="http://www.eyeforpharma.com" /></item><item><title>Attenace</title><link>http://www.drugs.com/NDA/attenace_041221.html</link><description>Drugs.com - prescription drug and over the counter medicine information available on over 24,000 approved medications and pharmaceuticals, including side effects and drug interactions.</description><guid>http://www.drugs.com/NDA/attenace_041221.html</guid><category domain="http://www.zibb.com">Cephalon Incorporated</category><pubDate /><source url="http://www.drugs.com" /></item><item><title>Apria - resources - News</title><link>http://www.apria.com/resources/1,2725,494-851242,00.html</link><description>ImmuPharma is now conducting a large Phase IIb study of Lupuzor in patients in Europe and Latin America. ImmuPharma will receive an upfront option payment of USD15m from Cephalon under the terms of the option agreement.</description><guid>http://www.apria.com/resources/1,2725,494-851242,00.html</guid><category domain="http://www.zibb.com">Cephalon Incorporated</category><pubDate /><source url="http://www.apria.com" /></item><item><title>Cephalon - Analyst News | newratings.com</title><link>http://www.newratings.com/headlines/Cephalon_US1567081096.html</link><description>Copyright © 2002 - 2008 newratings.com GmbH | Legal | Licensing Quote data provided by IS.eFinance Solutions (powered by IS.Teledata AG) using StandardPoor's ComStock Inc. and others. Delay times are 15 mins for European exchanges and NASDAQ, 20 mins for NYSE and AMEX.</description><guid>http://www.newratings.com/headlines/Cephalon_US1567081096.html</guid><category domain="http://www.zibb.com">Cephalon Incorporated</category><pubDate /><source url="http://www.newratings.com" /></item><item><title>RT Magazine - The Journal for Respiratory Care Practitioners</title><link>http://www.rtmagazine.com/prnews.php?p=215</link><description>. VIVITROL is indicated for patients who are able to abstain from drinking in an outpatient setting and are not actively drinking when initiating treatment.</description><guid>http://www.rtmagazine.com/prnews.php?p=215</guid><category domain="http://www.zibb.com">Cephalon Incorporated</category><pubDate /><source url="http://www.rtmagazine.com" /></item><item><title>Cephalon (CEPH) News - Company News and Press Releases</title><link>http://www.investorguide.com/stock-news.cgi?ticker=CEPH</link><description>Track Any Stock Instantly Just enter up to ten of your stocks in the Stock Tracker box, click the ADD button beside any of Today's Hot Stocks, or click ADD beside any of the stocks you've Recently Viewed.</description><guid>http://www.investorguide.com/stock-news.cgi?ticker=CEPH</guid><category domain="http://www.zibb.com">Cephalon Incorporated</category><pubDate /><source url="http://www.investorguide.com" /></item><item><title>pre employment questionnaires</title><link>http://www.cheviotartus.co.uk/pre_employment_questionnaires/pre_employment_questionnaires_379.html</link><description>Parties Also Agree to Business Arrangements Related to Modafinil FRAZER, Pa., Dec. 9 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) announced today that it has entered into an agreement with Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) and Teva Pharmaceuticals USA, Inc.</description><guid>http://www.cheviotartus.co.uk/pre_employment_questionnaires/pre_employment_questionnaires_379.html</guid><category domain="http://www.zibb.com">Cephalon Incorporated</category><pubDate /><source url="http://www.cheviotartus.co.uk" /></item><item><title>Supply &amp; Demand Chain Executive &gt; Research &gt; Archived Articles Ce...
      </title><link>http://www.isourceonline.com/article_arch.asp?article_id=7497</link><description>Waltham, MA — August 9, 2005 — Cephalon Inc., an international biopharmaceutical company, has selected OAT Foundation Suite as the radio frequency identification (RFID) software platform for use in a pilot program for tracking branded pharmaceuticals across the supply chain.</description><guid>http://www.isourceonline.com/article_arch.asp?article_id=7497</guid><category domain="http://www.zibb.com">Cephalon Incorporated</category><pubDate /><source url="http://www.isourceonline.com" /></item><item><title>Cephalon Inc Share Chart. CEH Historical Graphs. Techncial analys...
      </title><link>http://www.lse.co.uk/ShareChart.asp?ShareChart=CEH</link><description>Click Here Click Here Life Style Extra - Finance, News &amp; Entertainment Google Web www.lse.co.uk Life Style Extra Lines Home | Finance | News | Lifestyle | Chat Forums new - Life Style Extra Chat Forums! | Contact Register / Login Life Style Extra Lines 24 December 2006 - 20:20:07 BST Home : Finance</description><guid>http://www.lse.co.uk/ShareChart.asp?ShareChart=CEH</guid><category domain="http://www.zibb.com">Cephalon Incorporated</category><pubDate /><source url="http://www.lse.co.uk" /></item><item><title>crime shield</title><link>http://www.crimeshieldmidlands.co.uk/crime_shield/crime_shield_266.html</link><description>Transaction Opens European Oncology Market for Cephalon; Creates Additional Direct Presence in Europes Five Major Markets FRAZER, Pa. and OXFORD, England, Dec. 6 /PRNewswire-FirstCall/ -- Cephalon, Inc.</description><guid>http://www.crimeshieldmidlands.co.uk/crime_shield/crime_shield_266.html</guid><category domain="http://www.zibb.com">Cephalon Incorporated</category><pubDate /><source url="http://www.crimeshieldmidlands.co.uk" /></item><item><title>ranbaxy</title><link>http://www.ranbaxy.com/pressrelease_det.asp?sno=257</link><description>Gurgaon, Haryana, India - December 23, 2005 - Ranbaxy Laboratories Limited (Ranbaxy) announced that it has entered into an agreement with Cephalon, Inc. (Nasdaq: CEPH) to settle their pending patent infringement dispute in the United States related to PROVIGIL® (modafinil) Tablets [C-IV].</description><guid>http://www.ranbaxy.com/pressrelease_det.asp?sno=257</guid><category domain="http://www.zibb.com">Cephalon Incorporated</category><pubDate /><source url="http://www.ranbaxy.com" /></item><item><title>OATSystems : Setting the Standard in RFID</title><link>http://www.oatsystems.com/news/UsingRFID_19Aug05.html</link><description>The international biopharmaceutical company Cephalon Inc. is to use the OAT Foundation Suite from OAT Systems as the RFID software platform for its pilot programme for tracking branded pharmaceuticals across the supply chain.</description><guid>http://www.oatsystems.com/news/UsingRFID_19Aug05.html</guid><category domain="http://www.zibb.com">Cephalon Incorporated</category><pubDate /><source url="http://www.oatsystems.com" /></item><item><title>Cephalon Reduces Outstanding Convertible Debt by $337 Million</title><link>http://www.omniomix.com/inthenews.php?id=70236</link><description>FRAZER, Pa., Dec. 19 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) announced today that it has exchanged shares of its common stock and cash for approximately $161.6 million of its zero coupon convertible subordinated notes first putable June 2008 and $175.</description><guid>http://www.omniomix.com/inthenews.php?id=70236</guid><category domain="http://www.zibb.com">Cephalon Incorporated</category><pubDate /><source url="http://www.omniomix.com" /></item><item><title>Modafinil poised for expanded indication</title><link>http://www.pharmacist.com/articles/h_ts_0380.cfm</link><description>At its September 24–25 meeting, FDA’s Peripheral and Central Nervous System Drugs Advisory Committee voted to recommend a broader indication for modafinil (Provigil-Cephalon): treatment of excessive daytime sleepiness associated with obstructive sleep apnea and shift work sleep disorder.</description><guid>http://www.pharmacist.com/articles/h_ts_0380.cfm</guid><category domain="http://www.zibb.com">Cephalon Incorporated</category><pubDate /><source url="http://www.pharmacist.com" /></item></channel></rss>